Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

GlobeNewswire 3 days ago

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team

GlobeNewswire April 9, 2024

Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

GlobeNewswire March 27, 2024

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

GlobeNewswire March 25, 2024

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

GlobeNewswire March 11, 2024

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

GlobeNewswire March 5, 2024

Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

GlobeNewswire February 27, 2024

Plus Updates Financial and Cash Guidance for 2024

GlobeNewswire December 18, 2023

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

GlobeNewswire December 12, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

GlobeNewswire November 29, 2023

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

GlobeNewswire November 20, 2023

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

GlobeNewswire November 15, 2023

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?

PR Newswire November 13, 2023

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

GlobeNewswire November 3, 2023

Plus Therapeutics Announces Share Repurchase Program

GlobeNewswire October 31, 2023

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire October 31, 2023

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

GlobeNewswire October 25, 2023

Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023

GlobeNewswire October 23, 2023

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases

GlobeNewswire October 10, 2023

Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October

GlobeNewswire October 9, 2023